

12 June 2024 EMA/MB/145463/2024 - Adopted Management Board meeting

Agenda for the 124th meeting of the Management Board

Held on 12 June 2024, Room 1C (15:00 - 18:30) Held on 13 June 2024, Room 1C (09:00 - 16:00)

Chair: Lorraine Nolan

Item	Title	MB action	
1.	Draft agenda	For adoption, EMA/MB/145463/2024*	
2.	Declarations of competing interests related to the current agenda	Oral report	
3.	Minutes from the 123rd meeting, held on 21 March 2024, adopted via written procedure	EMA/MB/158744/2024	
Α	Points for automatic adoption		
A.1	Management Board meeting dates 2025-2026	For information & adoption, EMA/MB/248390/2024*	
A.2	Management Board decision – Adoption by analogy of amendment to Commission decision on transfer of pension rights C(2024) 1038 final	For information, EMA/MB/169190/2024; For adoption, EMA/MB/153252/2024	
В	Points for discussion		
B.1	Highlights of the Executive Director	Oral report	
B.2	Report from the European Commission	Oral report	
B.3	Update on 30 Churchill Place, includingAmending Budget 03-2024	For information, EMA/MB/245112/2024; For adoption, EMA/MB/229817/2024*	



Item	Title	MB action
B.4	a) Assessment of the Executive Director's Annual Activity Report (AAR) 2023	For information, EMA/MB/250703/2024, EMA/24036/2024*; For adoption, EMA/MB/250703/2024*
	b) Draft annual accounts 2023 and launch of written procedure	For information, EMA/MB/249660/2024, EMA/MB/249887/2024
B.5	Annual report 2023 on Key Performance Indicators (KPIs) for evaluation, post-authorisation, inspection, and scientific advice procedures for medicinal products for human and veterinary use	For information, EMA/MB/202002/2024; For endorsement, EMA/MB/182122/2024
B.6	a) Update on MB Audits and Risks Group (MBARG)activitiesb) Annual report of internal audit and advisory activitiesat the European Medicines Agency 2023	Oral report For information, EMA/MB/235277/2024; For adoption, EMA/MB/62775/2024
B.7	 New Fee Regulation, related documents: a) New Fee Regulation_Working arrangements b) Cooperation Agreement c) Memorandum of Understanding d) MB Decision on the common format for reporting performance and financial information e) MB Decision on the financial arrangements on remuneration for (co-)rapporteur services f) Revision of budget remark for budget 2025 	For information, EMA/MB/142342/2024; For adoption, EMA/MB/183645/2024*; For adoption, EMA/MB/244306/2024; For adoption, EMA/MB/244310/2024; For adoption, EMA/MB/183562/2024; For adoption, EMA/MB/183670/2024; For endorsement, EMA/MB/10351/2024
B.8	Review of remuneration scheme for training development & delivery: lessons learnt and next steps	Oral report
B.9	Quality Management Policy (Policy 0001)	For information, EMA/MB/66906/2024; For endorsement, EMA/228979/2024*
B.10	Report from the COMP	Oral report
B.11	EMA independence policies: Principles for the revision of EMA's policies on the handling of declarations of interests of scientific committees' members and experts (Policy 0044) and Management Board members (Policy 0058)	For discussion, EMA/MB/247295/2024

Item	Title	MB action
B.12	Report to the Management Board on ACT EU, the operation of CTIS and the Clinical Trial Regulation	For information, EMA/MB/215546/2024, EMA/MB/215547/2024
B.13	Big Data Steering Group progress report, including: • Update on AI activities	Oral report
B.14	Report on International activities at EMA	Oral report
С	Points for information only**	
C.1	Outcome of written procedures finalised during the period from 12 March to 3 June 2024	For information, EMA/MB/131031/2024*
C.2	Network Portfolio Report	For information, EMA/MB/255124/2024, EMA/231561/2024
C.3	Summary report of implementation of assigned revenue June24	For information: EMA/251256/2024
C.4	EMA working document on buildings	For information, EMA/MB/49527/2024, EMA/49471/2024
C.5	Summary report transfers of appropriations June24	For information, EMA/251253/2024
C.6	Management Board liaison on PRAC composition – Liaison after 12 years of PRAC in 2024	For information, EMA/MB/167876/2024

^{*} Documents marked with a star * are intended for publication on the external website.

** Documents in Additional documents for information section are not intended for discussion unless specifically requested.